Hodgkin’s lymphoma (HL) represents a distinctive malignancy within the realm of hematological neoplasms. First described by Dr. Thomas Hodgkin in the 19th century, it has since evolved from an enigmatic entity into a well - characterized disease, thanks to extensive research efforts. The review article aims to provide a comprehensive overview of Hodgkin’s lymphoma, integrating recent advances in etiology, pathogenesis, and therapeutic strategies, with a focus on seminal studies and breakthroughs.
Hodgkin’s lymphoma is a heterogeneous disorder predominantly affecting young adults. It is characterized by the presence of Reed - Sternberg cells and their variants within the lymphoid tissue. Over the years, refined diagnostic criteria have emerged, leading to improved classification system, most recently updates in 2016, has contributes to a more precise categorization of Hodgkin’s lymphoma subtypes, enabling tailored therapeutic approaches.
The etiology of Hodgkin’s lymphoma is complex and multi factorial. Genetic predisposition, environmental factors, and viral infections have all been implicated. Recent genetic studies have shed light on specific alternations, such as copy number variations and gene mutations, contributing to lymphomagenesis(1). Additionally, the role of the Epstein - Barr virus (EBV) in a subset of cases has been well - established (2).
Treatment strategies for Hodgkin’s lymphoma have evolved significantly over the past few decades. Traditionally, a combination of chemotherapy and radiation therapy has been the standard care, resulting in high cure rates. However, these therapies are associated with substantial long - term toxicities. Advances in precision medicine have ushered in a new era of therapy, with targeted agents and immunotherapies gaining prominence. The PD-1 inhibitor pembrolizumab, for instance, has demonstrated remarkable efficacy in relapsed/refractory cHL (3).
Personalized medicine has become increasingly relevant in HL management. Molecular Profiling, including next - generation sequencing, allows for the identification of specific mutations and molecular markers, guiding treatment decisions (4). Furthermore, risk - adapted approaches have been developed to optimize therapeutic outcomes while minimizing adverse effects particularly in early - stage HL (5).
Challenges in Hodgkin’s lymphoma represents a captivating model of malignancy, where scientific progress has transformed our understanding and management of the disease. This review will synthesize current knowledge about Hodgkin’s lymphoma, encompassing its etiology, classification, diagnostic advances, and evolving therapeutic options, with reference to key studies and pivotal discoveries. By amalgamating recent research findings, this review endeavors to contribute to the collective knowledge base, ultimately improving the care and outcomes of individuals affected by Hodgkin’s lymphoma.
Key Characteristics of Hodgkin’s lymphoma include:-
- Presence of specific abnormal cells called ‘Reed - Sternberg cells within affected lymph nodes.
- These cells, along with other cell types, make up the characteristic cellular makeup of this disease.
Hodgkin’s lymphoma is categorized into two main types:-
Classical Hodgkin Lymphoma:- This is the most common form of Hodgkin’s lymphoma and is further divided into subtypes, including nodular sclerosis, mixed cellularity, lymphocyte - rich, and lymphocyte - depleted. Each subtype has distinct characteristics, but they all involve the presence of Reed - Sternberg cells.
Nodular Lymphocyte - Predominant Hodgkin’s Lymphoma:- This is a less common subtype of Hodgkin’s lymphoma and is characterized by the presence of popcorn cells, which are large lymphoma cells with multiple nuclei.
Symptoms of Hodgkin’s Lymphoma can vary but may include:-
- Painless swelling of lymph nodes, typically in the neck, axillary, or groin.
- Fever and chills
- Night sweats
- Unexplained weight loss
- Fatigue
- Itchy skin
- Anorexia
- Pain in lymph nodes after consuming alcohol (Rare).
The exact cause of Hodgkin’s lymphoma is unknown, but it is thought to be related to genetic and environmental factors. It can affect people of all ages; although it is most commonly diagnosed in young adults (ages 15 to 35) and older adults (ages 55 and older).
Treatment for Hodgkin’s lymphoma typically involves a combination of therapies including chemotherapy, radiation therapy, and in some cases, stem cell transplantation. The choice of treatment depends on the stage of the disease, the subtype, and the patient’s overall health.
Prognosis for Hodgkin’s lymphoma is generally favourable, with a high rate of cure, especially in early - stage cases. Advances in treatment and research continue to improve outcomes and reduce long - term side effects for those affected by this cancer(6).
Hyperuricemia is not directly related to Hodgkin’s lymphoma, but it can be associated with this type of cancer due to certain factors and complications.
Hyperuricemia is a medical condition characterized by elevated levels of uric acid in the blood. Uric acid is a waste product that is normally excreted by the kidneys. When uric acid levels become too high, it can lead to the formation of uric acid crystals, which can accumulate in joints and other tissues, causing gout or kidney stones(7).
In the context of Hodgkin’s lymphoma, hyperuricemia may occur as a result of several factors:
Tumor Lysis Syndrome (TLS):- Hodgkin’s lymphoma, like other cancers, can sometimes lead to a condition called tumor lysis syndrome. TLS occurs when cancer cells break down rapidly, releasing their contents into the blood stream. This can lead to a surge in the release of uric acid, which can overwhelm the kidney’s ability to excrete it, resulting in hyperuricemia.
Chemotherapy and Radiation Therapy:- Treatment for Hodgkin’s lymphoma often involves chemotherapy and radiation therapy. These treatments can also cause cancer cells to break down rapidly, leading to TLS an increase in uric acid levels.
Impaired Kidney Function:- Some individuals with Hodgkin’s lymphoma may have impaired kidney function due to the disease itself or as a side effect of treatment. If the kidneys are not functioning optimally, they may have difficulty excreting uric acid, leading to hyperuricemia.
Anemia can be related to Hodgkin’s lymphoma in several ways:
A. Bone Marrow Involvement,
B. Chemotherapy and Radiation therapy,
C. Inflammatory Response,
D. Malnutrition,
E. Blood loss
It is important to note that anemia in individuals with Hodgkin’s lymphoma can vary in severity and may be temporary or chronic(8). Anemia can cause symptoms such as fatigue, weakness, pale skin, and shortness of breath,which can impact a person’s quality of life. Management of anemia in Hodgkin’s lymphoma patients may involve treating the underlying cancer, addressing nutritional deficiencies, and providing supportive care such as blood transfusions or medications to stimulate red blood cell production(9,10).
Brentuximab Vedotin:
On November 10,2022 the FDA approved Brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide for pediatric patients two years of age and older with previously untreated high risk classical Hodgkin lymphoma (cHL).
Brentuximab vedotin it is used to treat types of cancer, primarily Hodgkin Lymphoma and systemic anaplastic large cell lymphoma (ALCL). It is classified as an antibody - drug conjugate (ADC) and is designed to specifically target cancer cells while minimizing damage to healthy cells.
Mechanism of Action:
Brentuximab vedotin consists of two main components - a monoclonal antibody and a cytotoxic agent. The antibody part of the drug is designed to recognize and bind to a protein called CD30, which is found on the surface of certain cancer cells, particularly in Hodgkin Lymphoma and ALCL. Once the antibody attaches to CD30, the entire molecule is taken up by the cancer cell.
Intracellular Delivery:
Once inside the cancer cell, Brentuximab vedotin releases its cytotoxic payload, a substance called monomethyl auristatin E (MMAE). MMAE disrupts the cell’s micro tubules, which are crucial for cell division and growth. This disruption leads to cell cycle arrest and ultimately cell death.
Indications:
Brentuximab vedotin is primarily used in the treatment of 2 main types of lymphomas:-
- Classical Hodgkin lymphoma (cHL): Especially in cases where the cancer has relapsed after previous treatment or when stem cell transplantation is not a viable option.
- Systemic anaplastic large cell lymphoma (ALCL): Specifically in cases where the cancer has either relapsed or become refractory to other treatments.
Administration:
Brentuximab vedotin is typically administered by intravenous (IV) infusion, usually every few weeks. The specific dosing schedule and duration of treatment may vary based on the individual patient and the stage of their disease.
Side Effects:
- Fatigue
- Nausea
- Diarrhea
- Peripheral neuropathy
- Low white blood cell counts
- Severe allergic reactions
Precautions:
Patients should inform their healthcare provider of any allergies, other medical conditions, or medications they are taking. It’s important to discuss potential side effects and the benefits of the treatment with the healthcare team.
